123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, β3-, or γ-radiation-resistant cell lines

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 1000-1007

  Reske, Sven N ^a   Deisenhofer, Sandra ^a   Glutting, Gerhard ^a   Zlatopolskiy, Boris D ^a   Morgenroth, Agnieszka ^a   Vogg, Andreas T J ^a   Buck, Andreas K ^a   Friesen, Claudia ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Auger radiation; Chemoresistance; DNA nanoirradiation; Nuclear targeting; Radioresistance; Treatment

Indexed keywords

5 IODO 4' THIO 2' DEOXYURIDINE I 123; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; DEOXYURIDINE DERIVATIVE; DOXORUBICIN; FLOXURIDINE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; 5 IODO 4' THIO 2' DEOXYURIDINE; 5-IODO-4'-THIO-2'-DEOXYURIDINE; ANTINEOPLASTIC AGENT; DEOXYURIDINE; DRUG DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

APOPTOSIS; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BETA RADIATION; CELL KILLING; CELL METABOLISM; CELL STRAIN HL 60; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; FLOW CYTOMETRY; GAMMA RADIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INHIBITION KINETICS; IRRADIATION; LEUKEMIA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; TREATMENT FAILURE; WILD TYPE; DRUG RESISTANCE; NANOTECHNOLOGY; RADIATION DOSE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA RAYS; CELL LINE, TUMOR; DEOXYURIDINE; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; HL-60 CELLS; HUMANS; IODINE RADIOISOTOPES; NANOTECHNOLOGY; RADIATION TOLERANCE; RADIOPHARMACEUTICALS;

EID: 34250328632     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.040337     Document Type: Article

References (37)

1. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol. 1996;41:1973-1992.
2. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature. 1977;265:620-621.
3. Kassis AI. Cancer therapy with Auger electrons: are we almost there? J Nucl Med. 2003;44:1479-1481.
4. Stepanek J, Larsson B, Weinreich R. Auger-electron spectra of radionuclides for therapy and diagnostics. Acta Oncol. 1996;35:863-868.
5. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(suppl):S4-Sl2.
6. Sastry KS. Biological effects of the Auger emitter iodine-125: a review - report no. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys. 1992;19:1361-1370.
7. Parker WB, Shaddix SC, Rose LM, et al. Metabolism and metabolic actions of 4′-thiothymidine in L1210 cells. Biochem Pharmacol. 1995;50:687-695.
8. 125I- iodo-4′-thio-2′-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med. 2002;43: 1218-1226.
9. 125I-iodo-4′-thio-2′-deoxyuridine in rodents. J Nucl Med. 2003; 44:1671-1676.
10. Prusoff WH, Jaffe JJ, Gunther H. Studies in the mouse of the pharmacology of 5-iododeoxyuridine, an analogue of thymidine. Biochem Pharmacol. 1960;3: 110-121.
11. Dupertuis Y, Vazquez M, March J, et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res. 2001;61:7971-7977.
12. Buchegger F, Perillo-Adamer F, Dupertuis YM, Bischof Delaloye A. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging. 2006;33:1352-1363.
13. Rahim SG, Trivedi N, Bogunovic-Batchelor MV, et al. Synthesis and anti-herpes virus activity of 2′-deoxy-4′-thiopyrimidine nucleosides. J Med Chem. 1996; 39:789-795.
14. Wirsching J, Voss J, Adiwidjaja G, Giesler A, Kopf J. Synthesis and structural elucidation of 2′-deoxy-4′-thio-L-threo- pentofuranosylpyrimidine and -purine nucleosides. Eur J Org Chem. 2001;1077-1087.
15. Dyson MR, Coe PL, Walker RT. An improved synthesis of benzyl 3.5-di-O-benzyl-2-deoxy-1.4-dithio-D-erythro-pentofuranoside, an intermediate in the synthesis of 4′-thionucleosides. Carbohydr Res. 1991;216:237-248.
16. 213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res. 2007;67:1950-1958.
17. Friesen C, Kiess Y, Debatin KM. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ. 2004; 11(suppl 1):S73-S85.
18. Hartmann A, Agurell E, Beevers C, et al. Recommendations for conducting the in vivo alkaline Comet assay: 4th International Comet assay workshop. Mutagenesis. 2003;18:45-51.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
20. Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske SN, Debatin K-M. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukemia cells. Eur J Nucl Med Mol Imaging. 2003;30:1251-1261.
21. 131I. Appl Radiat Isot. 2005;62:861-869.
22. Friesen C, Fulda S, Debatin K-M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11:1833-1841.
23. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul. 1993;33:235-252.
24. Mackey JR, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Update. 1998;1:310-324.
25. Ellims PH, Gan TE, Van-der-Weyden MB. Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br J Haematol. 1981;49:479-481.
26. Eriksson S, Munch-Petersen B, Johansson K, Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci. 2002;59:1327-1346.
27. Ackland SP, Peters GJ. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Update. 1999;2:205-214.
28. Wataya Y, Santi DV, Hansch C. Inhibition of Lactobacillus casei thymidylate synthetase by 5-substituted 2′-deoxyuridylates: preliminary quantitative structure-activity relationship. J Med Chem. 1977;20:1469-1473.
29. Garrett C, Wataya Y, Santi DV. Thymidylate synthetase: catalysis of dehalogenation of 5-bromo- and 5-iodo-2′-deoxyuridylate. Biochemistry. 1979;18:2798-2804.
30. 125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. Int J Cancer. 2004; 110:145-149.
31. van Triest B, Pinedo HM, Blaauwgeers JL, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res. 2000;6: 1063-1072.
32. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004;56:53-102.
33. Romain S, Bendahl PO, Guirou O, Malmstrom P, Martin PM, Ferno M. DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Int J Cancer. 2001;95:56-61.
34. 125I-iododeoxyuridine. Eur J Nucl Med Mol Imaging. 2006;33:613-620.
35. 125I]iodo-2′-deoxyuridine in mammalian cells following treatment with 5-fluoro-2′-deoxyuridine. J Nucl Biol Med. 1991;35:167-173.
36. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology. 2003;193:3-34.
37. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood. 1997;90:3118-3129.